Table 1.
Patient characteristics
| Patient characteristics | ||
| Female | n = 36 | 33,9 % |
| Male | n = 70 | 66,1 % |
| Age (median (range), years) | 62.5 (33.0 -76.0) | |
| Karnofsky index (median (range), %) | 80 (60–100) | |
| Pretreatment characteristics | ||
| Prior resection or radiofrequency ablation | n = 30 | 28 % |
| Prior chemotherapy agents | ||
| Oxaliplatin (+5-fluorouracil) | n = 79 | 75 % |
| Irinotecan (+5-fluorouracil) | n = 89 | 84 % |
| Capecitabine | n = 27 | 25 % |
| Bevacizumab | n = 67 | 63 % |
| Cetuximab | n = 51 | 48 % |
| Other | n = 7 | 7 % |
| Overall chemotherapy lines (median (range)) | 3 (1–5) | |
| 1st Line | n = 9 | 8 % |
| 2nd Line | n = 35 | 33 % |
| 3rd Line | n = 34 | 32 % |
| 4th Line and beyond | n = 28 | 26 % |
| Tumor characteristics | ||
| UICC stage (median (range)) | 4 (1–4) | |
| Grading (median (range)) | 2 (1–4) | |
| Synchronous lymphatic metastases | n = 80 | 75 % |
| Extrahepatic tumor sites prior to radioembolization | n = 30 | 28 % |
| Solitary/oligonodular lung metastases | n = 1 | 1 % |
| Diffuse lung metastases | n = 15 | 14 % |
| Lymphatic metastases | n = 17 | 16 % |
| Bone metastases | n = 3 | 3 % |
| Hepatic tumor load (median (range), %) | 15.7 (1.0–63.0) | |
| CEA serum level (median (range), ng/ml) | 130.1 (2.7–8713.3) | |
| CA19-9 serum level (median (range), U/ml) | 192.7 (0.3–32206.0) | |
| Radioembolization procedures | n = 178 | 100 % |
| Bilobar (total liver) | n = 12 | 7 % |
| Unilobar | n = 52 | 30 % |
| Sequential lobar | n = 114 | 64 % |
| Treatment sessions per patient (median (range)) | 2 (1–5) | |
| Total activity per patient (median (range), MBq) | 1725.0 (200.0–3650) | |